#RA pts on #baricitinib less likely to discontinue treatment & more likely to achieve remission than pts receiving biologic /other tsDMARD. 👉🏼Results from RA-BE-REAL observational study 👉🏼Bari(2 or 4mg) vs biologic/other tsDMARD Abs#1223 #ACR21 @RheumNow https://t.co/WRN1OCX9Bq https://t.co/UCFF6hAY7G